Aug. 12 at 4:25 PM
$ACRS Aclaris Therapeutics (ACRS - Free Report) closed the last trading session at
$5.91, gaining 5.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of
$10 indicates a 69.2% upside potential.The average comprises 10 short-term price targets ranging from a low of
$4.00 to a high of
$16.00, with a standard deviation of
$3.4. While the lowest estimate indicates a decline of 32.3% from the current price level, the most optimistic estimate points to a 170.7% upside.
